secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beyond Air, Inc. (XAIR)
CIK:        0001641631
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-032063
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beyond Air Q2 net loss $12.0M ($0.40/sh); LungFit PH launch; UNO combo data positive
--------------------------------------------------------------------------------

- Net loss attributable to shareholders $12.0M ($0.40 per share) for Q2 FY2023 ended Sep 30, 2022.
- Cash and equivalents $72.5M as of Sep 30; cash burn $10.4M in quarter, within guidance of $8-10M.
- LungFit PH commercial launch progressing; CE Mark expected end of 2022; PMA supplement for cardiac label expansion planned.
- Preclinical data shows UNO + anti-PD-1 leads to higher tumor regression and prolonged survival in CT26 mice.
- Beyond Cancer Phase 1 solid tumor study first patient dosed Aug 2022; topline data expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641631/000149315222032063/0001493152-22-032063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641631/000149315222032063/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer